<DOC>
	<DOCNO>NCT01947296</DOCNO>
	<brief_summary>The purpose estimate evolution patient treat oral neoplastic agent , term early unforeseen recourse hospital adverse event .</brief_summary>
	<brief_title>Impact Coordinated Regional Organization Secure Patient 's Care Treated Oral Antineoplastic Agents</brief_title>
	<detailed_description>Introduction : Oral antineoplastic agent know full development particular target therapy . Their adverse event ( AE ) lately detect lead non compliance treatment discontinuation origin disease progression . They also lead hospitalization recourse emergency department associate cost society . Hypothesis : A coordinated intervention cancer network relation primary healthcare professional , would improve safety care 's patient treat oral antineoplastic agent prevent serious AEs rapid detection . Primary objective : The primary objective estimate effect coordinate intervention cancer network , term number early unforeseen recourse hospital AE , within first 6 month oral neoplastic agent introduction . Secondary objective : The secondary objective estimate effect coordinate intervention cancer network , within first 6 month oral neoplastic agent introduction , term number hospitalization AE , number consultation AE , number early unforeseen recourse hospital grade 1 / 2 AE , number AE per detection grade , AE maximal grade , AE grade , disease progression , global survival ( death cause AE ) , drug dose-intensity take patient treatment , number recourses health care system , quality life , patient 's satisfaction , medical economic evaluation Primary outcome : The main outcome number early unforeseen recourse hospital AE . Secondary outcome : The secondary outcome deaths death AE , number hospitalization AE , number consultation AE , number early unforeseen recourse hospital grade 1 / 2 AE , disease progression , drug dose-intensity take patient treatment , number recourses health care system , number AE per detection grade , AE maximal grade , AE grade , quality life , patient 's satisfaction , medical economic evaluationMethodology , design : A comparative , control , randomize , multicenter , prospective , `` quasi-experimental '' study , allow estimate evolution patient accord existence cancer network residence place . Number needed subject : 440 patient . Total duration study : 27 month . Inclusion Period : 21 month . length participation period one patient : 6 month . Number participate center : 21 . Average number inclusion month center : 4 .</detailed_description>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>patient affect cancer ( breast , colorectal , liver , lung , kidney , gastrointestinal stromal tumor , pancreas ) treat capecitabine , erlotinib , gefitinib , imatinib , lapatinib , sorafenib , sunitinib , vinorelbine , Evérolimus , Pazopanib , Etoposide , Topotécan 18 year old refusal participate lack proficiency French , Performance Status &gt; 2 , home base care , patient enrol clinical trial patient enrol therapeutic education program patient administrative supervision legal guardianship affiliate Patient Social Security CMU ( recipient beneficiary )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Oral antineoplastic agent</keyword>
	<keyword>Adverse Effects</keyword>
	<keyword>Cancer Networks</keyword>
	<keyword>Continuity care</keyword>
	<keyword>Coordination patient 's care</keyword>
</DOC>